CARDIOVASCULAR SAFETY IN THERAPY OF DIABETES MELLITUS TYPE 2
https://doi.org/10.21518/2079-701X-2016-19-122-125
Abstract
Diabe tes mellitus is chronical disease, lead to vascular complications. The safety of hypoglycemic therapy influences on cardiovascular complications. In this review results of some large-scale clinic trials directed to prevention of cardiovascular complications are provided.
About the Authors
A. F. VERBOVOY
Samara State Medical University of the Ministry of Health of Russia
Russian Federation
RAS Aacademician, MD, Prof.
Russian Federation
RAS Aacademician, MD, Prof.
A. V. PASHENTSEVA
Samara State Medical University of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
Y. A. DOLGIKH
Samara State Medical University of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. S. OSINA
Samara State Medical University of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
L. A. SHARONOVA
Samara State Medical University of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Дедов И.И. Всероссийский эндокринологический конгресс, 2015 год. Государственный регистр больных СД на 01.01.2015 в России.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J, 1998, 317: 703-713.
3. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Longterm results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 2000 Apr, 23(Suppl. 2): 21-29.
4. FDA Guidance for Industry. Diabetes mellitus –evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/uc m071627.pdf.
5. Ismail-Beigi F, Moghissi ES. Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocr Pract, 2008, 14: 639-643.
6. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects оf intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358: 2545-2559.
7. Вербовой А.Ф., Барабанова Н.А. Фармакоэпидемио логический анализ терапии сахарного диабета 2-го типа в амбулаторной практике. Проблемы эндокринологии, 2009, 4: 3-6.
8. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a metaanalysis of randomized clinical trials. Diabetes Obes Metab, 2013, 15(10): 938-953.
9. Dluhi RG, McMahonn GT. Intensive Glycemic Control in the АССОRD and ADVANCE Trials. N Eng J Med, 2008, 358: 2630-2633.
10. Woodward M, Patel A, Zoungas S et al. Does glycemic control offer similar benefits amongpatients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care, 2011 Dec, 34(12): 2491-2495.
11. Holman RR et al. 10–Year Follow–up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med, 2008, 359: 1577-1589.
12. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения : учеб. пос. - 2-е изд., перераб. и доп. М. : ГЭОТАР-Медиа, 2014. 1032 с.
13. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascul Pharmacol, 2011, 55(1-3): 10-16.
14. Goto H, Nomiyama T, Mita T et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun, 2011, 405: 79-84.
15. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). Сахарный диабет, 2015, 18(1S): 1-112.
16. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 2013, 369(14): 1317-1326.
17. White W et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med, 2013, 369: 1327-1335.
18. Merck. Merck announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) met primary endpoint. www.mercknewsroom.com/news- release/prescriptionmedicine-news/merck-announces-trial-evaluating-cardiovascular- outcomes-sit.
19. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: metaanalysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther, 2014, 32(4): 147-158.
20. Dixit D, Yoon Y, Volino LR et al. Empagliflozin: a sodium-glucose cotransporter2 inhibitor for treatment of type 2 diabetes. Am J Healts Syst Pharm, 2015, 72(22): 1943-1954.
21. Zinman B, Wanner C, Lachin JM et al. Оценка частоты осложнений и смертности при применении эмпаглифлозина в лечении сахарного диабета типа 2. The New England Journal of Medicine, 2015, 373(2): 2117-2128.
22. Abdul-Ghani M, Del Prato S, Chilton R et al. SGLT2 Inhibitors and Cardiovascular Risk: Lesson Learned From the EMPA-REG OUTCOME Studi. Diabetes Care, 2016, 39(5): 717-725.
23. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет, 2011, 4: 6-17.
24. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol, 1998 Mar-Apr, 25(3-4): 175-184.
25. Залевская А.Г., Вербовая Н.И., Родионова Т.И. и др. Базальная инсулинотерапия у пациентов с сахарным диабетом типа 2 с неудовлетворительным контролем гликемии на пероральной сахароснижающей терапии: результаты прямого сравнительного исследования аналогов инсулина Лантус и Левемир. Сахарный диабет, 2010, 2: 106- 112.
26. Скудаев С.А., Вербовая Н.И. Эффективность применения инсулина гларгин в условиях реальной клинической практики: результаты наблюдательной программы LAURUS-2. Проблемы эндокринологии, 2011, 6: 15-20.
27. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med, 2012, 367: 319-328.
28. Kansagara D, Fu R, Freeman M et al. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med, 2011, 154: 268-282.
Review
For citations:
VERBOVOY AF, PASHENTSEVA AV, DOLGIKH YA, OSINA AS, SHARONOVA LA. CARDIOVASCULAR SAFETY IN THERAPY OF DIABETES MELLITUS TYPE 2. Meditsinskiy sovet = Medical Council. 2016;(19):122-125. (In Russ.) https://doi.org/10.21518/2079-701X-2016-19-122-125
Views:
615
Email this article 